<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845582</url>
  </required_header>
  <id_info>
    <org_study_id>ALK001-P3001</org_study_id>
    <nct_id>NCT03845582</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of ALK-001 in Geographic Atrophy</brief_title>
  <acronym>SAGA</acronym>
  <official_title>A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkeus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkeus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-masked, multicenter, randomized, placebo-controlled clinical trial,
      evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA)
      secondary to age-related macular degeneration (AMD).

      Up to 200 participants will receive ALK-001 while up to 100 participants will receive a
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no treatment available for Geographic Atrophy secondary to AMD. AMD is characterized
      by an age-related degeneration of the retina.

      The root cause for this degeneration or why some people develop AMD while others do not, is
      unknown. Over 20 years ago, it was hypothesized that the dimerization of vitamin A may be a
      significant contributor to the etiology of AMD. The eye indeed uses vitamin A as a cofactor
      to sense light, and a striking chemical signature of the aging and degenerating retina is the
      accumulation of vitamin A dimers in the retinal pigment epithelium (RPE) and the underlying
      Bruch's membrane. In rodent models, high levels of vitamin A dimers correlate with poor
      retinal health, and a variety of mechanisms have been proposed by which vitamin A dimers may
      induce retinal toxicity. It has been argued that these mechanisms participate in the
      development and progression of AMD.

      ALK-001, the study drug, is a modified form of vitamin A. When taken once a day as a capsule,
      it replaces natural vitamin A in the body with one that forms vitamin A dimers more slowly.
      This study will measure the extent to which treatment with ALK-001 slows the progression of
      Geographic Atrophy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth rate of GA lesions, as assessed by Fundus Autofluorescence (FAF)</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability, as assessed by evaluation of adverse events</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, as assessed by plasma concentrations of ALK-001 and metabolites</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of choroidal neovascularization (CNV)</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Visual Acuity</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Reading Speed</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Geographic Atrophy</condition>
  <condition>Age Related Macular Degeneration</condition>
  <condition>AMD</condition>
  <condition>Atrophy, Geographic</condition>
  <arm_group>
    <arm_group_label>ALK-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALK-001 oral capsule</intervention_name>
    <description>Daily administration for 24 months</description>
    <arm_group_label>ALK-001</arm_group_label>
    <other_name>C20-D3-Retinyl Acetate</other_name>
    <other_name>C20 Deuterated vitamin A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Daily administration for 24 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

        - At least one eye with geographic atrophy secondary to dry age-related macular
        degeneration (AMD)

        Major Exclusion Criteria:

        - Medical condition, which may interfere with the progression of GA, prevent performance of
        study procedures, compliance with protocol, or continuous participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonide Saad, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alkeus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leonide Saad, PhD</last_name>
    <phone>800-287-2755</phone>
    <email>sagainfo@sagastudy.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Coordinating Center</name>
      <address>
        <city>Somerville</city>
        <state>Massachusetts</state>
        <zip>02144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kaufman Y, Ma L, Washington I. Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents. J Biol Chem. 2011 Mar 11;286(10):7958-65. doi: 10.1074/jbc.M110.178640. Epub 2010 Nov 12.</citation>
    <PMID>21075840</PMID>
  </reference>
  <reference>
    <citation>Mihai DM, Jiang H, Blaner WS, Romanov A, Washington I. The retina rapidly incorporates ingested C20-Dâ‚ƒ-vitamin A in a swine model. Mol Vis. 2013 Jul 25;19:1677-83. Print 2013.</citation>
    <PMID>23914132</PMID>
  </reference>
  <reference>
    <citation>Saad L, Washington I. Can Vitamin A be Improved to Prevent Blindness due to Age-Related Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies? Adv Exp Med Biol. 2016;854:355-61. doi: 10.1007/978-3-319-17121-0_47.</citation>
    <PMID>26427432</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Retinol acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

